公开(公告)号：US6080746A

公开(公告)日：2000-06-27

申请号：US776895

申请日：1991-10-16

Applicant: David I. Scheer

Inventor： David I. Scheer

IPC: A61K31/52 ,  A61K31/522 ,  A61P31/12 ,  C07D473/18 ,  A61K7/16 ,  A61K7/035 ,  A61K7/42

CPC classification number: A61K31/70 ,  A61K31/52 ,  A61K31/522

Abstract: Methods and compositions for preventing or treating cytomegalovirus infections by the use of carbocyclic analogues of purine and pyrimidine nucleosides.

Abstract translation: 通过使用嘌呤和嘧啶核苷的碳环类似物预防或治疗巨细胞病毒感染的方法和组合物。

公开(公告)号：US5019402A

公开(公告)日：1991-05-28

申请号：US483205

申请日：1990-02-20

Applicant: Robert D. Kross ,  David I. Scheer

Inventor： Robert D. Kross ,  David I. Scheer

IPC: A61K35/14 ,  A61L2/00

CPC classification number: A61L2/0094

Abstract: There is disclosed a composition and process for disinfecting or essentially sterilizing blood fractions and components of blood. The composition is formed by adding a chlorine dioxide liberating compound with a weak organic acid and a heat activated saccharide.

Abstract translation: 公开了用于消毒或基本上消毒血液部分和血液成分的组合物和方法。 通过将二氧化氯释放化合物与弱有机酸和热活化糖相加来形成组合物。

公开(公告)号：US5210096A

公开(公告)日：1993-05-11

申请号：US728896

申请日：1991-07-10

Applicant: David I. Scheer

Inventor： David I. Scheer

IPC: A61K31/555 ,  C07F15/06

CPC classification number: C07F15/065 ,  A61K31/555

Abstract: Compositions having significant activity as antiviral agent are disclosed containing, as an active component, a compound having the structural formula: ##STR1## wherein R.sub.1 and R.sub.1' are the same or different and each is an alkyl group, a phenyl group or a substituted derivative of a phenyl group;wherein R.sub.2 and R.sub.2' are the same or different and each is hydrogen, an unbranched alkyl group, a halide or a group having the structure ##STR2## wherein R is hydrogen, an alkoxide group, an alkyl group, or OH; wherein R.sub.3 and R.sub.3' are the same or different and each is hydrogen or an alkyl group;wherein X and X' are the same or different and each is a water soluble group having weak to intermediate ligand field strength; andQ.sup.- is a soluble, pharmaceutically acceptable negative ion.Methods of use of the inventive compositions are also disclosed.

Abstract translation: 公开了作为抗病毒剂具有显着活性的组合物，其含有具有以下结构式的化合物作为活性成分：其中R1和R1'相同或不同，并且各自为烷基，苯基或取代衍生物 的苯基; 其中R2和R2'相同或不同，各自为氢，未分支的烷基，卤化物或具有结构的基团，其中R为氢，烷氧基，烷基或OH; 其中R3和R3'相同或不同，各自为氢或烷基; 其中X和X'相同或不同，并且各自是具有弱至中间配体场强的水溶性基团; 和Q-是可溶的药学上可接受的负离子。 还公开了本发明组合物的使用方法。

公开(公告)号：US5106841A

公开(公告)日：1992-04-21

申请号：US502294

申请日：1990-03-30

Applicant: David I. Scheer

Inventor： David I. Scheer

IPC: A61K31/555 ,  A61P31/12 ,  C07F15/06

CPC classification number: C07F15/065 ,  A61K31/555

Abstract: Compositions having significant activity as antiviral agent are disclosed containing, as an active component, a compound having the structural formula: ##STR1## wherein R.sub.1 and R.sub.1' are the same or different and each is an alkyl group, a phenyl group or a substituted derivative of a phenyl group;wherein R.sub.2 and R.sub.2' are the same or different and each is hydrogen, an unbranched alkyl group, a halide or a group having the structure ##STR2## wherein R is hydrogen, an alkoxide group, an alkyl group, or OH; wherein R.sub.3 and R.sub.3' are the same or different and each is hydrogen or an alkyl group;wherein X and X' are the same or different and each is a water soluble group having weak to intermediate ligand field strength; andQ.sup.- is a soluble, pharmaceutically acceptable negative ion.Methods of use of the inventive compositions are also disclosed.

Abstract translation: 公开了作为抗病毒剂具有显着活性的组合物，其含有具有以下结构式的化合物作为活性组分：其中R 1和R 1'相同或不同，并且各自为烷基，苯基或取代衍生物 的苯基; 其中R2和R2'相同或不同，各自为氢，未分支的烷基，卤化物或具有结构的基团，其中R为氢，烷氧基，烷基或OH; 其中R3和R3'相同或不同，各自为氢或烷基; 其中X和X'相同或不同，并且各自是具有弱至中间配体场强的水溶性基团; 和Q-是可溶的药学上可接受的负离子。 还公开了本发明组合物的使用方法。

公开(公告)号：US6001840A

公开(公告)日：1999-12-14

申请号：US20220

申请日：1993-02-19

Applicant: John A. Montgomery ,  John A. Secrist, III ,  L. Lee Bennett ,  William B. Parker ,  Y. Fumer Shealy ,  David I. Scheer

Inventor： John A. Montgomery ,  John A. Secrist, III ,  L. Lee Bennett ,  William B. Parker ,  Y. Fumer Shealy ,  David I. Scheer

IPC: A61K31/52

CPC classification number: A61K31/522 ,  A61K31/52

Abstract: Method for prophylaxis and treatment of a viral infection characterized by the administration of a composition comprising a substantial molar excess of the D-stereoisomer of 2'CdG over the L-stereoisomer.

Abstract translation: 用于预防和治疗病毒感染的方法，其特征在于施用包含相当摩尔过量的L-立体异构体上2'CdG的D-立体异构体的组合物。

公开(公告)号：US4857514A

公开(公告)日：1989-08-15

申请号：US776918

申请日：1985-09-17

Applicant: Arnold S. Lippa ,  David I. Scheer

Inventor： Arnold S. Lippa ,  David I. Scheer

IPC: C12N7/04 ,  A61K20060101 ,  A61K31/685 ,  A61K39/00 ,  A61K39/21

CPC classification number: A61K31/685 ,  Y10S514/885 ,  Y10S514/934

Abstract: A virus having a lipid-containing capsid, such as AIDS virus, is inactivated by contacting the virus with an inactivating amount of phosphatidyl choline. Such a virus can be inactivated in fluids such as virus-contaminated body fluids or derivatives, e.g., blood or blood derivatives. The phosphatidyl choline can be present in an Active Lipid (AL) composition further comprising neutral lipids and phosphatidyl ethanolamine. Phosphatidyl choline, and an AL composition containing same, is useful for the treatment or prophylaxis of Acquired Immune Deficiency Syndrome (AIDS) in mammals.

Abstract translation: 通过使病毒与灭活量的磷脂酰胆碱接触，具有含脂质衣壳（例如AIDS病毒）的病毒被灭活。 这种病毒可以在诸如病毒污染的体液或衍生物例如血液或血液衍生物的流体中灭活。 磷脂酰胆碱可以存在于还包含中性脂质和磷脂酰乙醇胺的活性脂质（AL）组合物中。 磷脂酰胆碱和含有它们的AL组合物可用于治疗或预防哺乳动物获得性免疫缺陷综合征（AIDS）。